Study drug mix for unresectable gallbladder cancer
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial tests a combination of cancer medicines (gemcitabine plus albumin-paclitaxel) along with immune therapy (sintilimab) and a blood-vessel–targeting drug (bevacizumab). It’s for people with gallbladder cancer that can’t be removed by surgery, to see if the treatment controls the cancer and improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18–75 years old and sign consent before any study steps.
- Your gallbladder cancer must be confirmed by pathology testing (biopsy/cytology).
- You must not have had prior whole-body (systemic) anti-cancer treatment like chemotherapy or immunotherapy.
- You need at least one measurable tumor seen on scans, and you must be fit enough for treatment (ECOG 0–1).
- Your blood, liver, kidney, and clotting test results must meet specific safety cutoffs.
- If you can become pregnant, you must have a negative pregnancy test and use reliable birth control during treatment and for 120 days after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of four drugs (gemcitabine, nab-paclitaxel, lenvatinib, and tislelizumab) for people with advanced bile duct or gallbladder cancer that cannot be removed by surgery and has not been treated before.
This trial tests whether combining an immunotherapy drug (AK112) with chemotherapy can shrink advanced gallbladder cancer enough to make surgery possible. The goal is to give patients a chance at curative surgery who otherwise might not have one.
This trial is testing a combination of four drugs (gemcitabine, cisplatin, nab-paclitaxel, and durvalumab) for people with gallbladder cancer that has spread or cannot be removed by surgery. The goal is to see if this drug combination helps shrink or control the cancer.
This trial tests a combination of three medicines—an immunotherapy (sintilimab), an anti-angiogenic drug (bevacizumab), and two chemotherapy drugs (gemcitabine and cisplatin, called AG)—as a first treatment for bile duct cancer that cannot be removed by surgery. The goal is to see if this cocktail can shrink tumors or slow their growth better than standard therapy.
This trial tests a combination of two chemotherapy drugs (gemcitabine and nab-paclitaxel) with two immunotherapy drugs (iparomlimab and tuvorilimab) for people with advanced gallbladder cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink the cancer or slow its growth.
This Phase 2 trial tests a targeted treatment (GEMOX) given after gallbladder cancer surgery. It uses a blood test that looks for cancer-related DNA to monitor recurrence and guide care, aiming to improve outcomes for people with higher-risk disease.
Hear when a new Gallbladder Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.